Imperial College London begins human trials of new Covid-19 vaccine

Modesto Morganelli
Giugno 16, 2020

That should in turn trigger an immune response so that the body can fight off any future Covid-19 infection.

Also Read | Earthquake of 3.9 Magnitude Reported in Jammu & Kashmir, Tremors Felt Near Katra Region: Live Breaking News Headlines & Coronavirus Updates, June 16, 2020.

Soriot said the company will know for sure by the end of the summer whether its vaccine is 100 percent successful in protecting people from novel coronavirus infection.

"However, which populations are able and should receive a vaccine that is developed will depend on the results of clinical trials", the official added.

The researchers expect to publish findings once the safety data are available and are hopeful a viable vaccine could be available in the first half of 2021.

Many scientists have warned that the pandemic might only be stopped with an effective vaccine, which typically takes years to develop.

Our vaccine work is progressing quickly.

Business secretary Alok Sharma, said Imperial's was "one of the world's front-runners" and had Britain's full backing.

Pascal Soriot, AstraZeneca's chief executive, told reporters the company has completed the latest stage of testing of the possible vaccine and is looking forward to Phase III.

The British-Swedish drugmaker AstraZeneca says it is talking to Brazil, China, Japan, and Russian Federation about supplying the potential novel coronavirus vaccine it developed with scientists from the University of Oxford.

"We need to assess whether the vaccine can train the immune system to defend itself against COVID-19". 30,000 people will participate in the next trial.

Following this initial small group, the team will then recruit further healthy volunteers (aged 18-75) to trial the optimal dose of vaccine in a larger population. Synthetic strands of genetic code based on the genetic materials of Sars-CoV-2 were used by Imperial College of London instead of using a weakened form of the illness.

The Beijing-based company's vaccine, called CoronaVac, has not caused severe side effects and more than 90 per cent of those administered with the shot on a 14-day interval have induced neutralising antibodies two weeks after inoculation, Sinovac said. Once injected into the muscle, the body's own cells are instructed to make copies of a spiky protein on the coronavirus.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE